NasdaqCM:CGENBiotechs
Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative
Compugen (NasdaqCM:CGEN) opened 2026 with Q1 revenue of US$2.2 million and a loss of US$7.7 million in net income, equal to an EPS loss of US$0.08, against a trailing twelve month EPS of US$0.37 on revenue of US$72.7 million. Over recent quarters the company has seen revenue move from US$1.5 million in Q4 2024 to US$2.3 million in Q1 2025, then to US$1.3 million in Q2 2025, US$1.9 million in Q3 2025, a one off spike to US$67.3 million in Q4 2025, and US$2.2 million this quarter. EPS shifted...